AzurRX Biopharma, which is developing non-systemic biologics for gastrointestinal disorders, raised $5 million by offering 0.96 million shares at $5.50. AzurRX Biopharma plans to list on the Nasdaq under the symbol AZRX. WallachBeth Capital and Network 1...read more
AzurRX Biopharma, which is developing non-systemic biologics for gastrointestinal disorders, again lowered the proposed deal size for its upcoming IPO on Wednesday. The Brooklyn, NY-based company now plans to raise $6.6 million by offering 1.2 million...read more
After four weeks without a single IPO, the US IPO market is back from its annual August pause. Four deals are on the IPO calendar to raise $690 million in the week...read more
The week's leading IPO is a $250 million blank check company, a clear sign that the dog days of summer have taken hold in the US IPO market.
Strong returns from recent IPOs indicate an open market when activity resumes in September. The Renaissance IPO...read more
AzurRX Biopharma prices downsized $5 million IPO at lowered price of $5.50
AzurRX Biopharma, which is developing non-systemic biologics for gastrointestinal disorders, raised $5 million by offering 0.96 million shares at $5.50. AzurRX Biopharma plans to list on the Nasdaq under the symbol AZRX. WallachBeth Capital and Network 1...read more
Gastrointestinal biotech AzurRX Biopharma decreases proposed IPO deal size
AzurRX Biopharma, which is developing non-systemic biologics for gastrointestinal disorders, again lowered the proposed deal size for its upcoming IPO on Wednesday. The Brooklyn, NY-based company now plans to raise $6.6 million by offering 1.2 million...read more
US IPO Week Ahead: IPO market is back in session with 4 deals
After four weeks without a single IPO, the US IPO market is back from its annual August pause. Four deals are on the IPO calendar to raise $690 million in the week...read more
US IPO Week Ahead: Summer slowdown takes effect with just 2 IPOs planned
The week's leading IPO is a $250 million blank check company, a clear sign that the dog days of summer have taken hold in the US IPO market. Strong returns from recent IPOs indicate an open market when activity resumes in September. The Renaissance IPO...read more